Clovis Oncology (CLVS) Misses Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Clovis Oncology Announces 2019 Operating Results
February 24, 2020 4:05 PM ESTRubraca® (rucaparib) net product revenue totaled $143.0M for 2019 and $39.3M for Q4 2019 Net product revenue for 2019 up 50% over 2018 46% reduction in net cash utilized in 2H 2019 compared to 1H 2019 $296.7M in cash, cash equivalents and available for sale securities at December 31, 2019; continue to anticipate cash runway into 2H 2021 Transaction in January 2020 reduced outstanding convertible debt at year-end 2019 by $123.4M Supplemental NDA for Rubraca in patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer granted Priority Review by FDA with PDUFA date of May 15, 2020 Lucitanib combination studies... More
